利妥昔单抗治疗特发性膜性肾病的研究进展

Progress in treatment of idiopathic membranous nephropathy with rituximab

特发性膜性肾病(IMN)是成人肾病综合征的主要病因,随着抗磷脂酶A2受体(PLA2R)抗体、血小板反应蛋白7A域(THSD7A)抗体在IMN患者中的发现,膜性肾病已被视为器官特异性的自身免疫性疾病,B细胞在IMN中的致病作用逐渐为人们所认识。利妥昔单抗(RTX)是一种特异性针对B淋巴细胞表面CD20的单克隆抗体,能与CD20抗原高亲和力结合,通过抗体依赖和补体依赖的细胞毒作用,导致B淋巴细胞清除,且安全性较高。近年来,RTX已逐渐应用于MN的治疗中。本文就RTX治疗IMN的进展进行综述。

Idiopathic membranous nephropathy（ IMN） is the main cause of adult nephrotic syndrome. With the discovery of anti-phospholipase A2 receptor（ PLA2 R） antibody,as well as antithrombospondin domain 7 A（ THSD7 A） antibody in patients with IMN,membranous nephropathy has been regarded as an organ-specific autoimmune disease. The role of B cells in pathogenesis of IMN was gradually recognized by people. Rituximab,a monoclonal antibody specific for B lymphocyte surface CD20 antigen,can bind CD20 antigen with high affinity,leading to B lymphocyte clearance with high safety through antibody-dependent and complement-dependent cytotoxicity. In recent years,rituximab has gradually been used in treatment of IMN. This review summarized the progress in treatment of IMN with rituximab.